The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
The Inflammatory Chemokine CCL5 and Cancer Progression
Open accessAbstract
Until recently, inflammatory chemokines were viewed mainly as indispensable “gate keepers” of immunity and inflammation. However, updated research indicates that cancer cells subvert the normal chemokine system and these molecules and their receptors become important constituents of the tumor microenvironment with very different ways to exert tumor-promoting roles. The CCR5 and the CCL5 ligand have been detected in some hematological malignancies, lymphomas, and a great number of solid tumors, but extensive studies on the role of the CCL5/CCR axis were performed only in a limited number of cancers. This review summarizes updated information on the role of CCL5 and its receptor CCR5 in cancer cell proliferation, metastasis, and the formation of an immunosuppressive microenvironment and highlights the development of newer therapeutic strategies aimed to inhibit the binding of CCL5 to CCR5, to inhibit CCL5 secretion, or to inhibit the interactions among tumor cells and the microenvironment leading to CCL5 secretion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Cell Migration: Integrating Signals from Front to Back
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., Parsons, J. T., & Horwitz, A. R. (2003) · Science · doi:10.1126/science.1092053 · Cited by 4,978
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
The Chemokine Superfamily Revisited
Zlotnik, A., & Yoshie, O. (2012) · Immunity · doi:10.1016/j.immuni.2012.05.008 · Cited by 1,235
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
Baba, M., Nishimura, O., Kanzaki, N., Okamoto, M., Sawada, H., Iizawa, Y., Shiraishi, M., Aramaki, Y., Okonogi, K., Ogawa, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5698 · Cited by 751
MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death
Schickel, R., Boyerinas, B., Park, S.-M., & Peter, M. E. (2008) · Oncogene · doi:10.1038/onc.2008.274 · Cited by 719
Candido, J., & Hagemann, T. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9847-0 · Cited by 653
RANTES: a versatile and controversial chemokine
Appay, V., & Rowland-Jones, S. L. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(00)01812-3 · Cited by 650
The inflammatory chemokines CCL2 and CCL5 in breast cancer
Soria, G., & Ben-Baruch, A. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.018 · Cited by 593
Gene-engineered T cells for cancer therapy
Kershaw, M. H., Westwood, J. A., & Darcy, P. K. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3565 · Cited by 505
Schlecker, E., Stojanovic, A., Eisen, C., Quack, C., Falk, C. S., Umansky, V., & Cerwenka, A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201018 · Cited by 438
Molecular Pathways Linking Inflammation and Cancer
Mantovani, A. (2010) · Current Molecular Medicine · doi:10.2174/156652410791316968 · Cited by 414
The chemokine system and cancer
Balkwill, F. R. (2012) · The Journal of Pathology · doi:10.1002/path.3029 · Cited by 412
Kim, H. K., Song, K. S., Park, Y. S., Kang, Y. H., Lee, Y. J., Lee, K. R., Kim, H. K., Ryu, K. W., Bae, J. M., & Kim, S. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00596-8 · Cited by 401
Chemokine receptor CCR5: insights into structure, function, and regulation
Oppermann, M. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.04.007 · Cited by 376
Azenshtein, E., Luboshits, G., Shina, S., Neumark, E., Shahbazian, D., Weil, M., Wigler, N., Keydar, I., & Ben‐Baruch, A. (2002) · PubMed · Cited by 371
MicroRNAs Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts in Ovarian Cancer
Mitra, A. K., Zillhardt, M., Hua, Y., Tiwari, P., Murmann, A. E., Peter, M. E., & Lengyel, E. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0206 · Cited by 371
Chemokines in health and disease
Raman, D., Sobolik-Delmaire, T., & Richmond, A. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.01.005 · Cited by 366
‘Cancer associated fibroblasts’ – more than meets the eye
Madar, S., Goldstein, I., & Rotter, V. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.05.004 · Cited by 362
The Role of Chemokines in Melanoma Tumor Growth and Metastasis
Payne, A. S., & Cornelius, L. A. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.01725.x · Cited by 361
Negus, R. P. M., Stamp, G. W. H., Hadley, J., & Balkwill, F. R. (1997) · Europe PMC (PubMed Central) · Cited by 339
Overcoming hurdles in developing successful drugs targeting chemokine receptors
Schall, T. J., & Proudfoot, A. E. I. (2011) · Nature Reviews Immunology · doi:10.1038/nri2972 · Cited by 318
Abe, M., Hiura, K., Wilde, J., Shioyasono, A., Moriyama, K., Hashimoto, T., Kido, S., Oshima, T., Shibata, H., Ozaki, S., et al. (2004) · Blood · doi:10.1182/blood-2003-11-3839 · Cited by 318
Luboshits, G., Shina, S., Kaplan, O., Engelberg, S., Nass, D., Lifshitz-Mercer, B., Chaitchik, S., Keydar, I., & Ben‐Baruch, A. (1999) · PubMed · Cited by 302
Abe, M., Hiura, K., Wilde, J., Moriyama, K., Hashimoto, T., Ozaki, S., Wakatsuki, S., Kosaka, M., Kido, S., Inoue, D., et al. (2002) · Blood · doi:10.1182/blood.v100.6.2195 · Cited by 294
CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells
Velasco-Velázquez, M., Jiao, X., De La Fuente, M., Pestell, T. G., Ertel, A., Lisanti, M. P., & Pestell, R. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3917 · Cited by 282
Aldinucci, D., Gloghini, A., Pinto, A., De Filippi, R., & Carbone, A. (2010) · The Journal of Pathology · doi:10.1002/path.2711 · Cited by 275
Self-citationMolecular Profiling of Inflammatory Breast Cancer
Bièche, I., Lerebours, F., Tozlu, S., Espie, M., Marty, M., & Lidereau, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0306 · Cited by 245
Niwa, Y., Akamatsu, H., Niwa, H., Sumi, H., Ozaki, Y., & Abe, A. (2001) · PubMed · Cited by 245
Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes
Mattei, S., Colombo, M. P., Melani, C., Silvani, A., Parmiani, G., & Herlyn, M. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910560617 · Cited by 235
Chang, L.-Y., Lin, Y.-C., Mahalingam, J., Huang, C.-T., Chen, T.-W., Kang, C.-W., Peng, H.-M., Chu, Y.-Y., Chiang, J.-M., Dutta, A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2493 · Cited by 232
Expression of CCL5 (RANTES) and CCR5 in prostate cancer
Vaday, G. G., Peehl, D. M., Kadam, P. A., & Lawrence, D. M. (2006) · The Prostate · doi:10.1002/pros.20306 · Cited by 230
Lentzsch, S., Gries, M., Janz, M., Bargou, R., Dörken, B., & Mapara, M. Y. (2003) · Blood · doi:10.1182/blood-2002-08-2383 · Cited by 218
Chemokines in cancer related inflammation
Allavena, P., Germano, G., Marchesi, F., & Mantovani, A. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.11.013 · Cited by 215
Long, H., Xie, R., Xiang, T., Zhao, Z., Lin, S., Liang, Z., Chen, Z., & Zhu, B. (2012) · STEM CELLS · doi:10.1002/stem.1194 · Cited by 202
Baumforth, K. R. N., Birgersdotter, A., Reynolds, G. M., Wei, W., Kapatai, G., Flavell, J. R., Kalk, E., Piper, K., Lee, S., Machado, L., et al. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070845 · Cited by 200
Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis
Mi, Z., Bhattacharya, S. D., Kim, V. M., Guo, H., Talbot, L. J., & Kuo, P. C. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr009 · Cited by 179
CCL5 increases lung cancer migration via PI3K, Akt and NF-κB pathways
Huang, C.-Y., Fong, Y.-C., Lee, C.-Y., Chen, M.-Y., Tsai, H.-C., Hsu, H.-C., & Tang, C.-H. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.014 · Cited by 176
Terpos, E., Politou, M., Szydlo, R., Goldman, J. M., Apperley, J. F., & Rahemtulla, A. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04561.x · Cited by 167
Tumour-associated macrophages and cancer
Cook, J., & Hagemann, T. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.05.017 · Cited by 165
Vallet, S., Pozzi, S., Patel, K. J., Vaghela, N. N., Fulciniti, M., Veiby, P. O., Hideshima, T., Santo, L., Cirstea, D. D., Scadden, D. T., et al. (2011) · Leukemia · doi:10.1038/leu.2011.43 · Cited by 160
Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues
Maggio, E. M., van den Berg, A., Diepstra, A., Kluiver, J. L., Visser, L., & Poppema, S. (2002) · Annals of Oncology · doi:10.1093/annonc/13.s1.52 · Cited by 157
Oba, Y., Lee, J., Ehrlich, L. A., Chung, H. Y., Jelinek, D. F., Callander, N. S., Horuk, R., Choi, S. J., & Roodman, G. D. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.11.015 · Cited by 156
Jundt, F., Anagnostopoulos, I., Bommert, K., Emmerich, F., Müller, G., Foss, H., Royer, H., Stein, H., & Dörken, B. (1999) · Blood · doi:10.1182/blood.v94.6.2065 · Cited by 153
Aldinucci, D., Lorenzon, D., Cattaruzza, L., Pinto, A., Gloghini, A., Carbone, A., & Colombatti, A. (2007) · International Journal of Cancer · doi:10.1002/ijc.23119 · Cited by 152
Self-citationMeadows, S. A., Vega, F., Kashishian, A., Johnson, D., Diehl, V., Miller, L. L., Younes, A., & Lannutti, B. J. (2011) · Blood · doi:10.1182/blood-2011-10-386763 · Cited by 152
Yaal‐Hahoshen, N., Shina, S., Leider–Trejo, L., Barnea, I., Shabtai, E. L., Azenshtein, E., Greenberg, I., Keydar, I., & Ben‐Baruch, A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0074 · Cited by 151
Expression and function of chemokine receptors in human multiple myeloma
Möller, C., Strömberg, T., Juremalm, M., Nilsson, K., & Nilsson, G. P. (2003) · Leukemia · doi:10.1038/sj.leu.2402717 · Cited by 148
Cambien, B., Richard, P., Karimdjee-Soilihi, B., Martini, V., Ferruà, B., Pitard, B., Schmid‐Antomarchi, H., & Schmid‐Alliana, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028842 · Cited by 139
Mrowietz, U., Schwenk, U., Maune, S., Bartels, J., Küpper, M., Fichtner, I., Schröder, J., & Schadendorf, D. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690164 · Cited by 137
Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites.
Milliken, D., Scotton, C. J., Raju, S., Balkwill, F. R., & Wilson, J. L. (2002) · PubMed · Cited by 136
Fischer, M., Juremalm, M., Olsson, N., Backlin, C., Sundström, C., Nilsson, K., Enblad, G., & Nilsson, G. P. (2003) · International Journal of Cancer · doi:10.1002/ijc.11370 · Cited by 135
Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22
Niens, M., Visser, L., Nolte, I. M., van der Steege, G., Diepstra, A., Cordano, P., Jarrett, R. F., Meerman, G. J. T., Poppema, S., & van den Berg, A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06964.x · Cited by 129
Colombatti, M., Grasso, S., Porzia, A., Fracasso, G., Scupoli, M. T., Cingarlini, S., Poffe, O., Naim, H. Y., Heine, M., Tridente, G., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004608 · Cited by 127
Roscic, B., Fischer, M., Leemann, C., Manrique, A., Gordon, C. J., Moore, J. P., Proudfoot, A. E. I., & Trkola, A. (2003) · Blood · doi:10.1182/blood-2003-02-0488 · Cited by 124
Zhang, Y., Lv, D., Kim, H.-J., Kurt, R. A., Bu, W., Li, Y., & Ma, X. (2012) · Cell Research · doi:10.1038/cr.2012.178 · Cited by 119
Menu, E., Leenheer, E. D., Raeve, H. D., Coulton, L. A., Imanishi, T., Miyashita, K., Valckenborgh, E. V., Riet, I. V., Camp, B. V., Horuk, R., et al. (2006) · Clinical & Experimental Metastasis · doi:10.1007/s10585-006-9038-6 · Cited by 113
CCL5 as a potential immunotherapeutic target in triple-negative breast cancer
Lv, D., Zhang, Y., Kim, H.-J., Zhang, L., & Ma, X. (2013) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.69 · Cited by 98
CCL5 and CCR5 Interaction Promotes Cell Motility in Human Osteosarcoma
Wang, S., Wu, H.-H., Liu, S., Wang, P., Ou, W., Chou, W., Shen, Y., & Tang, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035101 · Cited by 97
Lin, S., Wan, S., Sun, L., Hu, J., Fang, D., Zhao, R., Yuan, S., & Zhang, L. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02259.x · Cited by 95
Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model
Ochoa‐Callejero, L., Pérez‐Martínez, L., Rubio-Mediavilla, S., Oteo, J. A., Martínez, A., & Blanco, J. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053992 · Cited by 93
Hanamoto, H., Nakayama, T., Miyazato, H., Takegawa, S., Hieshima, K., Tatsumi, Y., Kanamaru, A., & Yoshie, O. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63187-2 · Cited by 92
Kato, T., Fujita, Y., Nakane, K., Mizutani, K., Terazawa, R., Ehara, H., Kanimoto, Y., Kojima, T., Nozawa, Y., Deguchi, T., et al. (2013) · Cytokine · doi:10.1016/j.cyto.2013.06.313 · Cited by 90
Hashimoto, T., Abe, M., Oshima, T., Shibata, H., Ozaki, S., Inoue, D., & Matsumoto, T. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04864.x · Cited by 89
The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients
Cao, Y., Luetkens, T., Kobold, S., Hildebrandt, Y., Gordic, M., Lajmi, N., Meyer, S., Bartels, K., Zander, A. R., Bokemeyer, C., et al. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.06.012 · Cited by 86
CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease
Dairaghi, D. J., Oyajobi, B. O., Gupta, A., McCluskey, B., Miao, S., Powers, J. P., Seitz, L. C., Wang, Y., Zeng, Y., Zhang, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384784 · Cited by 86
Dehqanzada, Z. A., Storrer, C. E., Hueman, M. T., Foley, R. J., Harris, K. A., Jama, Y. H., Shriver, C. D., Ponniah, S., & Peoples, G. E. (2007) · Oncology Reports · doi:10.3892/or.17.3.687 · Cited by 82
STAT3-RANTES Autocrine Signaling Is Essential for Tamoxifen Resistance in Human Breast Cancer Cells
Yi, E. H., Lee, C. S., Lee, J., Lee, Y. J., Shin, M. K., Cho, C., Kang, K. W., Lee, S. E., Han, W., Noh, D., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0217 · Cited by 82
Gallo, M., Luca, A. D., Lamura, L., & Normanno, N. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr159 · Cited by 81
Swamydas, M., Ricci, K., Rego, S. L., & Dréau, D. (2013) · Cell Adhesion & Migration · doi:10.4161/cam.25138 · Cited by 76
Sugasawa, H., Ichikura, T., Kinoshita, M., Ono, S., Majima, T., Tsujimoto, H., Chochi, K., Hiroi, S., Takayama, E., Saitoh, D., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23401 · Cited by 75
The CCL5/CCR5 axis promotes metastasis in basal breast cancer
Velasco-Velázquez, M. A., & Pestell, R. G. (2013) · OncoImmunology · doi:10.4161/onci.23660 · Cited by 74
Mellado, M., de Ana, A. M., Moreno, M. C., Martínez‐A, C., & Rodríguez-Frade, J. M. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00199-3 · Cited by 72
Ben‐Baruch, A. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0094-3 · Cited by 69
Yang, X. F., Hou, J., Han, Z., Wang, Y., Hao, C., Wei, L., & Shi, Y. (2013) · Cell & Bioscience · doi:10.1186/2045-3701-3-5 · Cited by 65
Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer
Sugasawa, H., Ichikura, T., Tsujimoto, H., Kinoshita, M., Morita, D., Ono, S., Chochi, K., Tsuda, H., Seki, S., & Mochizuki, H. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.20984 · Cited by 61
Kim, J., Kim, H. S., Shin, Y., Lee, C. S., Won, C., Lee, S.-A., Lee, S. E., Kim, Y., Kang, J., Ye, S., et al. (2008) · Experimental & Molecular Medicine · doi:10.3858/emm.2008.40.5.514 · Cited by 60
The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment
Aldinucci, D., Gloghini, A., Pinto, A., Colombatti, A., & Carbone, A. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.605190 · Cited by 60
Self-citationTsukishiro, S., Suzumori, N., Nishikawa, H., Arakawa, A., & Suzumori, K. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.01.029 · Cited by 59
Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma
Seidl, H., Richtig, E., Tilz, H., Stefan, M., Schmidbauer, U., Asslaber, M., Zatloukal, K., Herlyn, M., & Schaider, H. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.11.013 · Cited by 59
CCR5 inhibitors: emergence, success, and challenges
Maeda, K., Das, D., Nakata, H., & Mitsuya, H. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.673584 · Cited by 58
Ρούσσου, Μ., Tasidou, A., Dimopoulos, M. A., Kastritis, E., Migkou, M., Christoulas, D., Gavriatopoulou, M., Zagouri, F., Matsouka, C., Anagnostou, D., et al. (2009) · Leukemia · doi:10.1038/leu.2009.130 · Cited by 55
Can we change the disease biology of multiple myeloma?
Borrello, I. (2012) · Leukemia Research · doi:10.1016/s0145-2126(12)70003-6 · Cited by 55
Zhang, X., Haney, K. M., Richardson, A. C., Wilson, E. N., Gewirtz, D. A., Ware, J. L., Zehner, Z. E., & Zhang, Y. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.003 · Cited by 51
IL-15 Can Signal via IL-15Rα, JNK, and NF-κB To Drive RANTES Production by Myeloid Cells
Chenoweth, M. J., Mian, M. F., Barra, N. G., Alain, T., Sonenberg, N., Bramson, J. L., Lichty, B. D., Richards, C. D., Ma, A. I., & Ashkar, A. A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101883 · Cited by 47
Udi, J., Schüler, J. B., Wider, D., Ihorst, G., Catusse, J., Waldschmidt, J. M., Schnerch, D., Follo, M., Wäsch, R., & Engelhardt, M. M. (2013) · British Journal of Haematology · doi:10.1111/bjh.12226 · Cited by 44
CCR1 as a target for multiple myeloma
Vallet, S., & Anderson, K. C. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.586634 · Cited by 41
MIP-1 Alpha and Myeloma Bone Disease
Roodman, G. D., & Choi, S. J. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-9129-4_4 · Cited by 40
IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion
Aldinucci, D., Celegato, M., Borghese, C., Colombatti, A., & Carbone, A. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08497.x · Cited by 37
Self-citationBorghese, C., Cattaruzza, L., Pivetta, E., Normanno, N., Luca, A. D., Mazzucato, M., Celegato, M., Colombatti, A., & Aldinucci, D. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24456 · Cited by 35
Self-citationSong, J. K., Park, M. H., Choi, D., Yoo, H. S., Han, S., Yoon, D. Y., & Hong, J. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033747 · Cited by 34
Zhang, Y., Arnatt, C. K., Zhang, F., Wang, J., Haney, K. M., & Fang, X. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.05.127 · Cited by 21
Zhang, F., Arnatt, C. K., Haney, K. M., Fang, H. C., Bajacan, J. E., Richardson, A. C., Ware, J. L., & Zhang, Y. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.07.049 · Cited by 20
Okita, K., Furuhata, T., Kimura, Y., Kawakami, M., Yamaguchi, K., Tsuruma, T., Zembutsu, H., & Hirata, K. (2005) · PubMed · Cited by 19
Smeets, A., Brouwers, B. A. H., Hatse, S., Laenen, A., Paridaens, R., Floris, G., Wildiers, H. P. M. W., & Christiaens, M.-R. (2013) · ISRN Immunology · doi:10.1155/2013/453561 · Cited by 10
Chemokine receptors as therapeutic tools in Hodgkin lymphoma: CCR4 and beyond
Aldinucci, D., Pinto, A., Gloghini, A., & Carbone, A. (2010) · Blood · doi:10.1182/blood-2009-10-247809 · Cited by 10
Self-citation
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Senescence and cancer — role and therapeutic opportunities
Schmitt, C. A., Wang, B., & Demaria, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00668-4 · Cited by 794
EMT and inflammation: inseparable actors of cancer progression
Suarez‐Carmona, M., Lesage, J., Cataldo, D., & Gilles, C. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12095 · Cited by 566
Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance
Khalaf, K., Hana, D., Chou, J. T.-T., Singh, C., Mackiewicz, A., & Kaczmarek, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656364 · Cited by 513
Senescent Cells in Cancer Therapy: Friends or Foes?
Wang, B., Kohli, J., & Demaria, M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.004 · Cited by 508
Metadata
- Authors
- Aldinucci, D., & Colombatti, A.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-12
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- OpenAlex
- W2040016252
- Cited by
- 438
- References
- 99
- FWCI
- 12.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.